A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.

A synergic effect between CYP2C192, CYP2C193 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.

Item

http://www.wikidata.org/entity/Q48217024

Q48217024

about

A synergic effect between CYP2C192, CYP2C193 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.

Item

http://www.wikidata.org/entity/Q48217024

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

A synergic effect between CYP2 ...... e Coronary Syndromes patients.

@en

A synergic effect between CYP2 ...... e Coronary Syndromes patients.

@nl

type

Item

label

A synergic effect between CYP2 ...... e Coronary Syndromes patients.

@en

A synergic effect between CYP2 ...... e Coronary Syndromes patients.

@nl

prefLabel

A synergic effect between CYP2 ...... e Coronary Syndromes patients.

@en

A synergic effect between CYP2 ...... e Coronary Syndromes patients.

@nl

P1476

A synergic effect between CYP2 ...... e Coronary Syndromes patients.

@en

P2093

Hafid Akoudad

http://www.w3.org/2001/XMLSchema#string

Hind Hassani Idrissi

http://www.w3.org/2001/XMLSchema#string

Nada El Khorb

http://www.w3.org/2001/XMLSchema#string

Rachida Habbal

http://www.w3.org/2001/XMLSchema#string

Wiam Hmimech

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

Structure and stereochemistry of the active metabolite of clopidogrel.

Pharmacogenetics: from bench to byte--an update of guidelines.

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

Genetic determinants of response to clopidogrel and cardiovascular events.

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Clopidogrel: a case for indication-specific pharmacogenetics.

P2888

s13104-018-3132-0

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13104-018-3132-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sellama Nadifi

P577

2018-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100474420

http://www.w3.org/2001/XMLSchema#string

P698

29347970

http://www.w3.org/2001/XMLSchema#string

P921

clopidogrel

P932

5774088

http://www.w3.org/2001/XMLSchema#string

A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.

about

A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

A synergic effect between CYP2C192, CYP2C193 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.

A synergic effect between CYP2C192, CYP2C193 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.